The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Cost Implications of the Rapid Adoption of Newer Technologies for Treating Prostate Cancer
Open accessAbstract
Purpose: Intensity-modulated radiation therapy (IMRT) and laparoscopic or robotic minimally invasive radical prostatectomy (MIRP) are costlier alternatives to three-dimensional conformal radiation therapy (3D-CRT) and open radical prostatectomy for treating prostate cancer. We assessed temporal trends in their utilization and their impact on national health care spending. Methods: Using Surveillance, Epidemiology, and End Results–Medicare linked data, we determined treatment patterns for 45,636 men age ≥ 65 years who received definitive surgery or radiation for localized prostate cancer diagnosed from 2002 to 2005. Costs attributable to prostate cancer care were the difference in Medicare payments in the year after versus the year before diagnosis. Results: Patients received surgery (26%), external RT (38%), or brachytherapy with or without RT (36%). Among surgical patients, MIRP utilization increased substantially (1.5% among 2002 diagnoses v 28.7% among 2005 diagnoses, P < .001). For RT, IMRT utilization increased substantially (28.7% v 81.7%; P < .001) and for men receiving brachytherapy, supplemental IMRT increased significantly (8.5% v 31.1%; P < .001). The mean incremental cost of IMRT versus 3D-CRT was $10,986 (in 2008 dollars); of brachytherapy plus IMRT versus brachytherapy plus 3D-CRT was $10,789; of MIRP versus open RP was $293. Extrapolating these figures to the total US population results in excess spending of $282 million for IMRT, $59 million for brachytherapy plus IMRT, and $4 million for MIRP, compared to less costly alternatives for men diagnosed in 2005. Conclusion: Costlier prostate cancer therapies were rapidly and widely adopted, resulting in additional national spending of more than $350 million among men diagnosed in 2005 and suggesting the need for comparative effectiveness research to weigh their costs against their benefits.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Methods for Rates and Proportions
Fleiss, J. L., Levin, B., & Paik, M. C. (2003) · Wiley Series in Probability and Statistics · doi:10.1002/0471445428 · Cited by 18,646
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M. J. (2009) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20006 · Cited by 9,709
Development of a comorbidity index using physician claims data
Klabunde, C. N., Potosky, A. L., Legler, J. M., & Warren, J. L. (2000) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(00)00256-0 · Cited by 1,845
Warren, J. L., Klabunde, C. N., Schrag, D., Bach, P. B., & Riley, G. F. (2002) · PubMed · doi:10.1097/01.mlr.0000020942.47004.03 · Cited by 1,714
Comparative Effectiveness of Minimally Invasive vs Open Radical Prostatectomy
Hu, J. C. (2009) · JAMA · doi:10.1001/jama.2009.1451 · Cited by 816
Self-citationWarren, J. L., Klabunde, C. N., Schrag, D., Bach, P. B., & Riley, G. F. (2002) · Medical Care · doi:10.1097/00005650-200208001-00002 · Cited by 772
ZELEFSKY, M. J., FUKS, Z., HUNT, M., LEE, H. J., LOMBARDI, D., LING, C. C., REUTER, V. E., VENKATRAMAN, E. S., & LEIBEL, S. A. (2001) · Journal of Urology · doi:10.1016/s0022-5347(05)65855-7 · Cited by 697
Estimating Health Care Costs Related to Cancer Treatment From SEER-Medicare Data
Brown, M. L., Riley, G. F., Schussler, N., & Etzioni, R. (2002) · Medical Care · doi:10.1097/00005650-200208001-00014 · Cited by 612
Zelefsky, M. J., Chan, H., Hunt, M., Yamada, Y., Shippy, A. M., & Amols, H. (2006) · Journal of Urology · doi:10.1016/j.juro.2006.06.002 · Cited by 467
Evaluation of Trends in the Cost of Initial Cancer Treatment
Warren, J. L., Yabroff, K. R., Meekins, A., Topor, M., Lamont, E. B., & Brown, M. L. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn175 · Cited by 388
Cited by
Goldin, G. H. (2012) · JAMA · doi:10.1001/jama.2012.460 · Cited by 445
Nanoparticle-Mediated Combination Therapy: Two-in-One Approach for Cancer
Gurunathan, S., Kang, M.-H., Qasim, M., & Kim, J.-H. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103264 · Cited by 367
Cooperberg, M. R., Simko, J. P., Cowan, J. E., Reid, J. E., Djalilvand, A., Bhatnagar, S., Gutin, A., Lanchbury, J. S., Swanson, G. P., Stone, S., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.4396 · Cited by 351
Yu, H.-Y., Hevelone, N. D., Lipsitz, S. R., Kowalczyk, K. J., & Hu, J. C. (2012) · Journal of Urology · doi:10.1016/j.juro.2011.11.089 · Cited by 291
Self-citationWallis, C. J. D., Saskin, R., Choo, R., Herschorn, S., Kodama, R. T., Satkunasivam, R., Shah, P. S., Danjoux, C., & Nam, R. K. (2016) · European Urology · doi:10.1016/j.eururo.2015.11.010 · Cited by 282
Metadata
- Authors
- Nguyen, P. L., Gu, X., Lipsitz, S. R., Choueiri, T. K., Choi, W. W., Lei, Y., Hoffman, K. E., & Hu, J. C.
- Venue
- Journal of Clinical Oncology
- Published
- 2011-04-20
- Volume
- 29
- Issue
- 12
- Pages
- 1517-1524
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2158631186
- Cited by
- 308
- References
- 19
- FWCI
- 35.88
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cost Implications of the Rapid Adoption of Newer Technologies for Treating Prostate Cancer. https://app.cochat.ai/papers/10.1200/jco.2010.31.1217
- The paper
- Nguyen, P. L., Gu, X., Lipsitz, S. R., Choueiri, T. K., Choi, W. W., Lei, Y., Hoffman, K. E., & Hu, J. C. (2011). Cost Implications of the Rapid Adoption of Newer Technologies for Treating Prostate Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2010.31.1217
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.